Related Experiment Video
Updated: May 29, 2026
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study
Shoichi Ozaki1, Tatsuya Atsumi, Taichi Hayashi
1Division of Rheumatology, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki 216-8511, Japan. ozk@marianna-u.ac.jp
Modern Rheumatology
|September 20, 2011
Summary
This study shows that a severity-based treatment approach for myeloperoxidase-anti-neutrophil cytoplasmic antibodies (MPO-ANCA)-associated vasculitis in Japanese patients effectively induces remission. The treatment strategy, tailored to disease severity, yielded remission rates comparable to Western trials.
Area of Science:
- Nephrology
- Rheumatology
- Immunology
Background:
- Myeloperoxidase-anti-neutrophil cytoplasmic antibodies (MPO-ANCA)-associated vasculitis is a serious autoimmune condition.
- Optimal treatment strategies for MPO-ANCA-associated vasculitis, particularly in Japanese populations, require further investigation.
Purpose of the Study:
- To evaluate the efficacy of a severity-based treatment regimen for MPO-ANCA-associated vasculitis in Japanese patients.
- To assess remission rates, mortality, and end-stage renal disease (ESRD) over an 18-month follow-up period.
Main Methods:
- A prospective, open-label, multi-center trial involving 48 Japanese patients with MPO-ANCA-associated vasculitis.
- Patients received tailored treatment based on disease severity: low-dose corticosteroids with optional cyclophosphamide/azathioprine (mild), high-dose corticosteroids and cyclophosphamide (severe), or severe regimen plus plasmapheresis (most severe).
Main Results:
- Of 47 treated patients, 42 (89%) achieved remission within 6 months.
- Five patients died, and one developed ESRD during the 18-month follow-up.
- Relapse occurred in 8 of the 42 patients who achieved remission.
Conclusions:
- Severity-based treatment for MPO-ANCA-associated vasculitis in Japan is effective in inducing remission.
- The observed remission and mortality rates are comparable to those reported in previous Western clinical trials.
- Tailoring treatment to individual disease severity appears to be a viable and effective approach for managing MPO-ANCA-associated vasculitis.
Related Concept Videos
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...